Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study
Hematological Oncology · 2026-11 · 44 (6)
DOI: 10.1002/hon.70288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 04.11.2026. Verfasst von Josefina Serrano und 38 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Reina Sofía-IMIBIC, UCO, Córdoba, Spain. Hauptthemen laut MEDLINE: Daunorubicin, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
CPX‐351, a liposomal formulation of cytarabine and daunorubicin, has been approved patients with secondary/high‐risk acute myeloid leukemia including therapy‐related acute myeloid leukemia or AML with myelodysplasia‐related changes according to the WHO 2016 classification. The aim of this study was to determine the efficacy and safety of CPX‐351 in 283 patients with AML registered in the PETHEMA database. Evolving outcome results were analyzed comparing early treated patients (before‐2022, N = 147) with those treated after Spanish financial approval (since‐2022, N = 136). The CR/CRi rate was 54% in the overall cohort, without significant differences comparing both time periods. By contrast, early death rates at day + 30 and day + 60 were higher in early period patients (11.6 vs. 5.1% and 17 vs. 8.1%, p = 0.03 and p = 0.031). Consequently, more patients could undergo HSCT in the latter treatment period (33.8% vs. 25.2%, p = 0.04). Patients treated with CPX‐351 since 2022 showed a significantly higher unadjusted 2‐year OS probability compared with patients treated earlier [40.3% (95% CI: 26.3–62.4) versus 25.2% (95% CI: 18.6–34.1), P = 0.017]. However, treatment period was not independently associated with OS in multivariable analysis. Only TP53 wild‐type status [HR 0.51 (95% CI: 0.25–1.05)] and achievement of MRD negativity after induction [HR 0.54 (95% CI: 0.29–1.0)] remained independently associated with improved OS. Overall, outcomes after CPX‐351 appeared to improve over time in unadjusted analyses; however, the absence of an independent effect of treatment period and differences in patient selection between periods preclude attributing this improvement specifically to a temporal learning effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Reina Sofía-IMIBIC, UCO, Córdoba, Spain.
- Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Hospital Universitario 12 de Octubre, Universidad Complutense Madrid, Madrid, Spain.
- Hospital San Pedro Alcántara, Cáceres, Spain.
- Hospital Universitario Príncipe de Asturias, Madrid, Spain.
- Hospital La Princesa, Madrid, Spain.
ORCID-Profile: Josefina Serrano, Rosa Ayala, Juan Bergua, Julio García-Suárez, Daniel García-Belmonte, Maria-Angeles Foncillas, Juan M Alonso, Almudena Laiglesia, Esther Prados de la Torre, Montse Arnan, Carlos Rodríguez-Medina, Susana Vives, Mar Tormo, Jorge Labrador, Cristina Gil, Raimundo García-Boyero, Ana Alfonso, Olga Arce, Victor Noriega, Esperanza Lavilla, Laura Torres, Joaquin Sánchez-García, Pau Montesinos
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Serrano, J., Aguirre, A., Martínez-Cuadrón, D., Ayala, R., Bergua, J., García-Suárez, J., Gómez-García de Soria, V., Marí, P., García-Belmonte, D., Martínez-Chamorro, C., Benavente, C., Olave, M., Bernal, T., Rodríguez-Arboli, E., Foncillas, M. A., Algarra, L., Alonso, J. M., Laiglesia, A., Prados de la Torre, E., …, & PETHEMA Group (2026). Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70288
Vancouver
Serrano J, Aguirre A, Martínez-Cuadrón D, Ayala R, Bergua J, García-Suárez J, et al. Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70288
BibTeX
@article{Serrano2026,
author = {Serrano, Josefina and Aguirre, Alicia and Martínez-Cuadrón, David and Ayala, Rosa and Bergua, Juan and García-Suárez, Julio and Gómez-García de Soria, Valle and Marí, Pilar and García-Belmonte, Daniel and Martínez-Chamorro, Carmen and Benavente, Celina and Olave, Mayte and Bernal, Teresa and Rodríguez-Arboli, Eduardo and Foncillas, Maria-Angeles and Algarra, Lorenzo and Alonso, Juan M and Laiglesia, Almudena and Prados de la Torre, Esther and Arnan, Montse and Rodríguez-Medina, Carlos and Riaza, Rosalía and Vives, Susana and Tormo, Mar and Colorado, Mercedes and Labrador, Jorge and Salamero, Olga and Gil, Cristina and García-Boyero, Raimundo and Lorente, Soraya and Alfonso, Ana and Arce, Olga and Noriega, Victor and Lavilla, Esperanza and DeRueda, Beatriz and Torres, Laura and Sánchez-García, Joaquin and Montesinos, Pau and PETHEMA Group, PETHEMA Group},
title = {Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {6},
doi = {10.1002/hon.70288}
}
EUVIMED